Targeting MAPK pathway in melanoma therapy

Cancer and Metastasis Reviews

Volumn 32, Issue 3-4, 2013, Pages 567-584

  Cheng, Yabin ^a   Zhang, Guohong ^a,c   Li, Gang ^a,b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b Shantou University Medical College ^*  (Canada)

^c SHANTOU UNIVERSITY MEDICAL COLLEGE   (China)

Author keywords

BRAF; MAPK; MEK; Melanoma; RAS

Indexed keywords

B RAF KINASE; B RAF KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; VEMURAFENIB;

ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CANCER SURVIVAL; DRUG MECHANISM; DRUG TARGETING; ENZYME INHIBITION; GENE MUTATION; HUMAN; MELANOMA; METASTATIC MELANOMA; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HUMANS; MAP KINASE SIGNALING SYSTEM; MELANOMA; MITOGEN-ACTIVATED PROTEIN KINASES; MOLECULAR TARGETED THERAPY; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-RAF; PROTO-ONCOGENE PROTEINS P21(RAS);

EID: 84890311325     PISSN: 01677659     EISSN: 15737233     Source Type: Journal    
DOI: 10.1007/s10555-013-9433-9     Document Type: Review

References (171)

1. Inamdar, G. S., Madhunapantula, S. V., & Robertson, G. P. (2010). Targeting the MAPK pathway in melanoma: why some approaches succeed and other fail. Biochemical Pharmacology, 80(5), 624-637.
2. Houghton, A. N., & Polsky, D. (2002). Focus on melanoma. Cancer Cell, 2(4), 275-278.
3. Miller, A. J., & Mihm, M. C., Jr. (2006). Melanoma. The New England Journal of Medicine, 355(1), 51-65.
4. Balch, C. M., Gershenwald, J. E., Soong, S. J., Thompson, J. F., Atkins, M. B., Byrd, D. R., et al. (2009). Final version of 2009 AJCC melanoma staging and classification. Journal of Clinical Oncology, 27(36), 6199-6206.
5. Bedikian, A. Y., Millward, M., Pehamberger, H., Conry, R., Gore, M., Trefzer, U., et al. (2006). Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. Journal of Clinical Oncology, 24(29), 4738-4745.
6. Lui, P., Cashin, R., Machado, M., Hemels, M., Corey-Lisle, P. K., & Einarson, T. R. (2007). Treatments for metastatic melanoma: synthesis of evidence from randomized trials. Cancer Treatment Reviews, 33(8), 665-680.
7. Eggermont, A. M., & Schadendorf, D. (2009). Melanoma and immunotherapy. Hematology/Oncology Clinics of North America, 23(3), 547-564. ix-x.
8. Finn, L., Markovic, S. N., & Joseph, R. W. (2012). Therapy for metastatic melanoma: the past, present, and future. BMC Medicine, 10, 23.
9. Sharma, A., Tran, M. A., Liang, S., Sharma, A. K., Amin, S., Smith, C. D., et al. (2006). Targeting mitogen-activated protein kinase/extracellular signal-regulated kinase kinase in the mutant (V600E) B-Raf signaling cascade effectively inhibits melanoma lung metastases. Cancer Research, 66(16), 8200-8209.
10. Panka, D. J., Atkins, M. B., & Mier, J. W. (2006). Targeting the mitogen-activated protein kinase pathway in the treatment of malignant melanoma. Clinical Cancer Research, 12(7 Pt 2), 2371s-2375s.
11. Johnson, G. L., & Lapadat, R. (2002). Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science, 298(5600), 1911-1912.
12. Minden, A., Lin, A., McMahon, M., Lange-Carter, C., Derijard, B., Davis, R. J., et al. (1994). Differential activation of ERK and JNK mitogen-activated protein kinases by Raf-1 and MEKK. Science, 266(5191), 1719-1723.
13. Lange-Carter, C. A., & Johnson, G. L. (1994). Ras-dependent growth factor regulation of MEK kinase in PC12 cells. Science, 265(5177), 1458-1461.
14. Marais, R., Light, Y., Paterson, H. F., Mason, C. S., & Marshall, C. J. (1997). Differential regulation of Raf-1, A-Raf, and B-Raf by oncogenic ras and tyrosine kinases. The Journal of Biological Chemistry, 272(7), 4378-4383.
15. Mason, C. S., Springer, C. J., Cooper, R. G., Superti-Furga, G., Marshall, C. J., & Marais, R. (1999). Serine and tyrosine phosphorylations cooperate in Raf-1, but not B-Raf activation. The EMBO Journal, 18(8), 2137-2148.
16. Aplin, A. E., Stewart, S. A., Assoian, R. K., & Juliano, R. L. (2001). Integrin-mediated adhesion regulates ERK nuclear translocation and phosphorylation of Elk-1. The Journal of Cell Biology, 153(2), 273-282.
17. Adachi, T., Kar, S., Wang, M., & Carr, B. I. (2002). Transient and sustained ERK phosphorylation and nuclear translocation in growth control. Journal of Cellular Physiology, 192(2), 151-159.
18. Jia, W., Yu, C., Rahmani, M., Krystal, G., Sausville, E. A., Dent, P., et al. (2003). Synergistic antileukemic interactions between 17-AAG and UCN-01 involve interruption of RAF/MEK- and AKT-related pathways. Blood, 102(5), 1824-1832.
19. Harada, H., Quearry, B., Ruiz-Vela, A., & Korsmeyer, S. J. (2004). Survival factor-induced extracellular signal-regulated kinase phosphorylates BIM, inhibiting its association with BAX and proapoptotic activity. Proceedings of the National Academy of Sciences of the United States of America, 101(43), 15313-15317.
20. Domina, A. M., Vrana, J. A., Gregory, M. A., Hann, S. R., & Craig, R. W. (2004). MCL1 is phosphorylated in the PEST region and stabilized upon ERK activation in viable cells, and at additional sites with cytotoxic okadaic acid or taxol. Oncogene, 23(31), 5301-5315.
21. Brazil, D. P., Park, J., & Hemmings, B. A. (2002). PKB binding proteins. Getting in on the Akt. Cell, 111(3), 293-303.
22. Cohen, C., Zavala-Pompa, A., Sequeira, J. H., Shoji, M., Sexton, D. G., Cotsonis, G., et al. (2002). Mitogen-actived protein kinase activation is an early event in melanoma progression. Clinical Cancer Research, 8(12), 3728-3733.
23. Satyamoorthy, K., Li, G., Gerrero, M. R., Brose, M. S., Volpe, P., Weber, B. L., et al. (2003). Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation. Cancer Research, 63(4), 756-759.
24. Liu, Z. J., Xiao, M., Balint, K., Smalley, K. S., Brafford, P., Qiu, R., et al. (2006). Notch1 signaling promotes primary melanoma progression by activating mitogen-activated protein kinase/phosphatidylinositol 3-kinase-Akt pathways and up-regulating N-cadherin expression. Cancer Research, 66(8), 4182-4190.
25. Russo, A. E., Torrisi, E., Bevelacqua, Y., Perrotta, R., Libra, M., McCubrey, J. A., et al. (2009). Melanoma: molecular pathogenesis and emerging target therapies (review). International Journal of Oncology, 34(6), 1481-1489.
26. Gollob, J. A., Wilhelm, S., Carter, C., & Kelley, S. L. (2006). Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway. Seminars in Oncology, 33(4), 392-406.
27. Klein, R. M., & Aplin, A. E. (2009). Rnd3 regulation of the actin cytoskeleton promotes melanoma migration and invasive outgrowth in three dimensions. Cancer Research, 69(6), 2224-2233.
28. Klein, R. M., Spofford, L. S., Abel, E. V., Ortiz, A., & Aplin, A. E. (2008). B-RAF regulation of Rnd3 participates in actin cytoskeletal and focal adhesion organization. Molecular Biology of the Cell, 19(2), 498-508.
29. Shevde, L. A., & Welch, D. R. (2003). Metastasis suppressor pathways - an evolving paradigm. Cancer Letters, 198(1), 1-20.
30. Smalley, K. S. (2003). A pivotal role for ERK in the oncogenic behaviour of malignant melanoma? International Journal of Cancer, 104(5), 527-532.
31. Govindarajan, B., Bai, X., Cohen, C., Zhong, H., Kilroy, S., Louis, G., et al. (2003). Malignant transformation of melanocytes to melanoma by constitutive activation of mitogen-activated protein kinase kinase (MAPKK) signaling. The Journal of Biological Chemistry, 278(11), 9790-9795.
32. Boni, A., Cogdill, A. P., Dang, P., Udayakumar, D., Njauw, C. N., Sloss, C. M., et al. (2010). Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. Cancer Research, 70(13), 5213-5219.
33. Sumimoto, H., Imabayashi, F., Iwata, T., & Kawakami, Y. (2006). The BRAF-MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells. The Journal of Experimental Medicine, 203(7), 1651-1656.
34. Rajalingam, K., Schreck, R., Rapp, U. R., & Albert, S. (2007). Ras oncogenes and their downstream targets. Biochimica et Biophysica Acta, 1773(8), 1177-1195.
35. Wennerberg, K., Rossman, K. L., & Der, C. J. (2005). The Ras superfamily at a glance. Journal of Cell Science, 118(Pt 5), 843-846.
36. Omholt, K., Platz, A., Kanter, L., Ringborg, U., & Hansson, J. (2003). NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression. Clinical Cancer Research, 9(17), 6483-6488.
37. Zheng, H., Liu, A., Liu, B., Li, M., Yu, H., & Luo, X. (2010). Ras homologue enriched in brain is a critical target of farnesyltransferase inhibitors in non-small cell lung cancer cells. Cancer Letters, 297(1), 117-125.
38. Yuan, Y., Hu, H. G., Ye, X. X., Shen, H., & Zheng, S. (2010). K-ras gene mutation in colorectal cancer and its clinicopathologic significance. Zhonghua Wai Ke Za Zhi, 48(16), 1247-1251.
39. Lopez-Bergami, P., Fitchman, B., & Ronai, Z. (2008). Understanding signaling cascades in melanoma. Photochemistry and Photobiology, 84(2), 289-306.
40. Ackermann, J., Frutschi, M., Kaloulis, K., McKee, T., Trumpp, A., & Beermann, F. (2005). Metastasizing melanoma formation caused by expression of activated N-RasQ61K on an INK4a-deficient background. Cancer Research, 65(10), 4005-4011.
41. van 't Veer, L. J., Burgering, B. M., Versteeg, R., Boot, A. J., Ruiter, D. J., Osanto, S., et al. (1989). N-ras mutations in human cutaneous melanoma from sun-exposed body sites. Molecular and Cellular Biology, 9(7), 3114-3116.
42. Edlundh-Rose, E., Egyhazi, S., Omholt, K., Mansson-Brahme, E., Platz, A., Hansson, J., et al. (2006). NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing. Melanoma Research, 16(6), 471-478.
43. Goel, V. K., Lazar, A. J., Warneke, C. L., Redston, M. S., & Haluska, F. G. (2006). Examination of mutations in BRAF, NRAS, and PTEN in primary cutaneous melanoma. The Journal of Investigative Dermatology, 126(1), 154-160.
44. Lee, J. H., Choi, J. W., & Kim, Y. S. (2011). Frequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: a meta-analysis. The British Journal of Dermatology, 164(4), 776-784.
45. Devitt, B., Liu, W., Salemi, R., Wolfe, R., Kelly, J., Tzen, C. Y., et al. (2011). Clinical outcome and pathological features associated with NRAS mutation in cutaneous melanoma. Pigment Cell & Melanoma Research, 24(4), 666-672.
46. Tsao, H., Chin, L., Garraway, L. A., & Fisher, D. E. (2012). Melanoma: from mutations to medicine. Genes & Development, 26(11), 1131-1155.
47. Jackson, J. H., Cochrane, C. G., Bourne, J. R., Solski, P. A., Buss, J. E., & Der, C. J. (1990). Farnesol modification of Kirsten-ras exon 4B protein is essential for transformation. Proceedings of the National Academy of Sciences of the United States of America, 87(8), 3042-3046.
48. Dhomen, N., & Marais, R. (2009). BRAF signaling and targeted therapies in melanoma. Hematology/Oncology Clinics of North America, 23(3), 529-545. ix.
49. Fensterle, J. (2006). A trip through the signaling pathways of melanoma. Journal der Deutschen Dermatologischen Gesellschaft, 4(3), 205-217.
50. End, D. W., Smets, G., Todd, A. V., Applegate, T. L., Fuery, C. J., Angibaud, P., et al. (2001). Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro. Cancer Research, 61(1), 131-137.
51. Appels, N. M., Beijnen, J. H., & Schellens, J. H. (2005). Development of farnesyl transferase inhibitors: a review. The Oncologist, 10(8), 565-578.
52. Epling-Burnette, P. K., & Loughran, T. P., Jr. (2010). Suppression of farnesyltransferase activity in acute myeloid leukemia and myelodysplastic syndrome: current understanding and recommended use of tipifarnib. Expert Opinion on Investigational Drugs, 19(5), 689-698.
53. Gajewski, T. F., Salama, A. K., Niedzwiecki, D., Johnson, J., Linette, G., Bucher, C., et al. (2012). Phase II study of the farnesyltransferase inhibitor R115777 in advanced melanoma (CALGB 500104). Journal of Translational Medicine, 10, 246.
54. Crul, M., de Klerk, G. J., Swart, M., van't Veer, L. J., de Jong, D., Boerrigter, L., et al. (2002). Phase I clinical and pharmacologic study of chronic oral administration of the farnesyl protein transferase inhibitor R115777 in advanced cancer. Journal of Clinical Oncology, 20(11), 2726-2735.
55. Punt, C. J., van Maanen, L., Bol, C. J., Seifert, W. F., & Wagener, D. J. (2001). Phase I and pharmacokinetic study of the orally administered farnesyl transferase inhibitor R115777 in patients with advanced solid tumors. Anti-Cancer Drugs, 12(3), 193-197.
56. Margolin, K. A., Moon, J., Flaherty, L. E., Lao, C. D., Akerley, W. L., 3rd, Othus, M., et al. (2012). Randomized phase II trial of sorafenib with temsirolimus or tipifarnib in untreated metastatic melanoma (S0438). Clinical Cancer Research, 18(4), 1129-1137.
57. Field, K. A., Charoenthongtrakul, S., Bishop, J. M., & Refaeli, Y. (2008). Farnesyl transferase inhibitors induce extended remissions in transgenic mice with mature B cell lymphomas. Molecular Cancer, 7, 39.
58. Adjei, A. A., Davis, J. N., Bruzek, L. M., Erlichman, C., & Kaufmann, S. H. (2001). Synergy of the protein farnesyltransferase inhibitor SCH66336 and cisplatin in human cancer cell lines. Clinical Cancer Research, 7(5), 1438-1445.
59. Basso, A. D., Mirza, A., Liu, G., Long, B. J., Bishop, W. R., & Kirschmeier, P. (2005). The farnesyl transferase inhibitor (FTI) SCH66336 (lonafarnib) inhibits Rheb farnesylation and mTOR signaling. Role in FTI enhancement of taxane and tamoxifen anti-tumor activity. The Journal of Biological Chemistry, 280(35), 31101-31108.
60. Smalley, K. S., & Eisen, T. G. (2003). Farnesyl transferase inhibitor SCH66336 is cytostatic, pro-apoptotic and enhances chemosensitivity to cisplatin in melanoma cells. International Journal of Cancer, 105(2), 165-175.
61. Niessner, H., Beck, D., Sinnberg, T., Lasithiotakis, K., Maczey, E., Gogel, J., et al. (2011). The farnesyl transferase inhibitor lonafarnib inhibits mTOR signaling and enforces sorafenib-induced apoptosis in melanoma cells. The Journal of Investigative Dermatology, 131(2), 468-479.
62. Weisz, B., Giehl, K., Gana-Weisz, M., Egozi, Y., Ben-Baruch, G., Marciano, D., et al. (1999). A new functional Ras antagonist inhibits human pancreatic tumor growth in nude mice. Oncogene, 18(16), 2579-2588.
63. Aharonson, Z., Gana-Weisz, M., Varsano, T., Haklai, R., Marciano, D., & Kloog, Y. (1998). Stringent structural requirements for anti-Ras activity of S-prenyl analogues. Biochimica et Biophysica Acta, 1406(1), 40-50.
64. Kelleher, F. C., & McArthur, G. A. (2012). Targeting NRAS in melanoma. Cancer Journal, 18(2), 132-136.
65. Jansen, B., Schlagbauer-Wadl, H., Kahr, H., Heere-Ress, E., Mayer, B. X., Eichler, H., et al. (1999). Novel Ras antagonist blocks human melanoma growth. Proceedings of the National Academy of Sciences of the United States of America, 96(24), 14019-14024.
66. Smalley, K. S., & Eisen, T. G. (2002). Farnesyl thiosalicylic acid inhibits the growth of melanoma cells through a combination of cytostatic and pro-apoptotic effects. International Journal of Cancer, 98(4), 514-522.
67. Johnson, M. L., Rizvi, N. A., Ginsberg, M. S., Miller, V. A., Kric, M. G., Pao, W., et al. (2009). A phase II trial of salirasib in patients with stage IIIB/IV lung adenocarcinoma enriched for KRAS mutations Journal of Clinical Oncology, 27 (15 Suppl.), Abstract 8012.
68. Laheru, D., Rudek, G., Taylor, H., Goldsweig, H., Rajeshkumar. N. V., Linden, S., et al. (2009). Integrated development of s-trans, trans-farnesylthiosalicyclic acid (FTS, salirasib) in advanced pancreatic cancer. Journal of Clinical Oncology, 27 (15 Suppl.), abstract 4529.
69. Rose, W. C., Lee, F. Y., Fairchild, C. R., Lynch, M., Monticello, T., Kramer, R. A., et al. (2001). Preclinical antitumor activity of BMS-214662, a highly apoptotic and novel farnesyltransferase inhibitor. Cancer Research, 61(20), 7507-7517.
70. Dinsmore, C. J., Bogusky, M. J., Culberson, J. C., Bergman, J. M., Homnick, C. F., Zartman, C. B., et al. (2001). Conformational restriction of flexible ligands guided by the transferred noe experiment: potent macrocyclic inhibitors of farnesyltransferase. Journal of the American Chemical Society, 123(9), 2107-2108.
71. Camacho, N. R., Sanchez, J. E., Martin, R. F., Gonzalez, J. R., & Sanchez, J. L. (2001). Medium-dose UVA1 phototherapy in localized scleroderma and its effect in CD34-positive dendritic cells. Journal of the American Academy of Dermatology, 45(5), 697-699.
72. Eskandarpour, M., Kiaii, S., Zhu, C., Castro, J., Sakko, A. J., & Hansson, J. (2005). Suppression of oncogenic NRAS by RNA interference induces apoptosis of human melanoma cells. International Journal of Cancer, 115(1), 65-73.
73. Kloog, Y., Cox, A. D., & Sinensky, M. (1999). Concepts in Ras-directed therapy. Expert Opinion on Investigational Drugs, 8(12), 2121-2140.
74. Garnett, M. J., & Marais, R. (2004). Guilty as charged: B-RAF is a human oncogene. Cancer Cell, 6(4), 313-319.
75. Mercer, K. E., & Pritchard, C. A. (2003). Raf proteins and cancer: B-Raf is identified as a mutational target. Biochimica et Biophysica Acta, 1653(1), 25-40.
76. Rajakulendran, T., Sahmi, M., Lefrancois, M., Sicheri, F., & Therrien, M. (2009). A dimerization-dependent mechanism drives RAF catalytic activation. Nature, 461(7263), 542-545.
77. Wellbrock, C., Karasarides, M., & Marais, R. (2004). The RAF proteins take centre stage. Nature Reviews Molecular Cell Biology, 5(11), 875-885.
78. Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., et al. (2002). Mutations of the BRAF gene in human cancer. Nature, 417(6892), 949-954.
79. Michaloglou, C., Vredeveld, L. C., Mooi, W. J., & Peeper, D. S. (2008). BRAF(E600) in benign and malignant human tumours. Oncogene, 27(7), 877-895.
80. Long, G. V., Menzies, A. M., Nagrial, A. M., Haydu, L. E., Hamilton, A. L., Mann, G. J., et al. (2011). Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. Journal of Clinical Oncology, 29(10), 1239-1246.
81. Pollock, P. M., Harper, U. L., Hansen, K. S., Yudt, L. M., Stark, M., Robbins, C. M., et al. (2003). High frequency of BRAF mutations in nevi. Nature Genetics, 33(1), 19-20.
82. Yazdi, A. S., Palmedo, G., Flaig, M. J., Puchta, U., Reckwerth, A., Rutten, A., et al. (2003). Mutations of the BRAF gene in benign and malignant melanocytic lesions. The Journal of Investigative Dermatology, 121(5), 1160-1162.
83. Niihori, T., Aoki, Y., Narumi, Y., Neri, G., Cave, H., Verloes, A., et al. (2006). Germline KRAS and BRAF mutations in cardio-facio-cutaneous syndrome. Nature Genetics, 38(3), 294-296.
84. Rodriguez-Viciana, P., Tetsu, O., Tidyman, W. E., Estep, A. L., Conger, B. A., Cruz, M. S., et al. (2006). Germline mutations in genes within the MAPK pathway cause cardio-facio-cutaneous syndrome. Science, 311(5765), 1287-1290.
85. Garraway, L. A., Widlund, H. R., Rubin, M. A., Getz, G., Berger, A. J., Ramaswamy, S., et al. (2005). Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature, 436(7047), 117-122.
86. Jane-Valbuena, J., Widlund, H. R., Perner, S., Johnson, L. A., Dibner, A. C., Lin, W. M., et al. (2010). An oncogenic role for ETV1 in melanoma. Cancer Research, 70(5), 2075-2084.
87. Tsao, H., Goel, V., Wu, H., Yang, G., & Haluska, F. G. (2004). Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma. The Journal of Investigative Dermatology, 122(2), 337-341.
88. Patton, E. E., Widlund, H. R., Kutok, J. L., Kopani, K. R., Amatruda, J. F., Murphey, R. D., et al. (2005). BRAF mutations are sufficient to promote nevi formation and cooperate with p53 in the genesis of melanoma. Current Biology, 15(3), 249-254.
89. Dhomen, N., Reis-Filho, J. S., da Rocha Dias, S., Hayward, R., Savage, K., Delmas, V., et al. (2009). Oncogenic Braf induces melanocyte senescence and melanoma in mice. Cancer Cell, 15(4), 294-303.
90. Dankort, D., Curley, D. P., Cartlidge, R. A., Nelson, B., Karnezis, A. N., Damsky, W. E., Jr., et al. (2009). Braf(V600E) cooperates with Pten loss to induce metastatic melanoma. Nature Genetics, 41(5), 544-552.
91. Chudnovsky, Y., Adams, A. E., Robbins, P. B., Lin, Q., & Khavari, P. A. (2005). Use of human tissue to assess the oncogenic activity of melanoma-associated mutations. Nature Genetics, 37(7), 745-749.
92. Wu, H., Goel, V., & Haluska, F. G. (2003). PTEN signaling pathways in melanoma. Oncogene, 22(20), 3113-3122.
93. Stahl, J. M., Sharma, A., Cheung, M., Zimmerman, M., Cheng, J. Q., Bosenberg, M. W., et al. (2004). Deregulated Akt3 activity promotes development of malignant melanoma. Cancer Research, 64(19), 7002-7010.
94. Hingorani, S. R., Jacobetz, M. A., Robertson, G. P., Herlyn, M., & Tuveson, D. A. (2003). Suppression of BRAF(V599E) in human melanoma abrogates transformation. Cancer Research, 63(17), 5198-5202.
95. Karasarides, M., Chiloeches, A., Hayward, R., Niculescu-Duvaz, D., Scanlon, I., Friedlos, F., et al. (2004). B-RAF is a therapeutic target in melanoma. Oncogene, 23(37), 6292-6298.
96. Wellbrock, C., Ogilvie, L., Hedley, D., Karasarides, M., Martin, J., Niculescu-Duvaz, D., et al. (2004). V599EB-RAF is an oncogene in melanocytes. Cancer Research, 64(7), 2338-2342.
97. Hoeflich, K. P., Gray, D. C., Eby, M. T., Tien, J. Y., Wong, L., Bower, J., et al. (2006). Oncogenic BRAF is required for tumor growth and maintenance in melanoma models. Cancer Research, 66(2), 999-1006.
98. Joseph, E. W., Pratilas, C. A., Poulikakos, P. I., Tadi, M., Wang, W., Taylor, B. S., et al. (2010). The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner. Proceedings of the National Academy of Sciences of the United States of America, 107(33), 14903-14908.
99. Wilhelm, S. M., Carter, C., Tang, L., Wilkie, D., McNabola, A., Rong, H., et al. (2004). BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Research, 64(19), 7099-7109.
100. Liu, L., Cao, Y., Chen, C., Zhang, X., McNabola, A., Wilkie, D., et al. (2006). Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Research, 66(24), 11851-11858.
101. Kim, S., Yazici, Y. D., Calzada, G., Wang, Z. Y., Younes, M. N., Jasser, S. A., et al. (2007). Sorafenib inhibits the angiogenesis and growth of orthotopic anaplastic thyroid carcinoma xenografts in nude mice. Molecular Cancer Therapeutics, 6(6), 1785-1792.
102. Sharma, A., Trivedi, N. R., Zimmerman, M. A., Tuveson, D. A., Smith, C. D., & Robertson, G. P. (2005). Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors. Cancer Research, 65(6), 2412-2421.
103. Eisen, T., Ahmad, T., Flaherty, K. T., Gore, M., Kaye, S., Marais, R., et al. (2006). Sorafenib in advanced melanoma: a phase II randomised discontinuation trial analysis. British Journal of Cancer, 95(5), 581-586.
104. Hauschild, A., Agarwala, S. S., Trefzer, U., Hogg, D., Robert, C., Hersey, P., et al. (2009). Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. Journal of Clinical Oncology, 27(17), 2823-2830.
105. Flaherty, K. T., Lee, S. J., Zhao, F., Schuchter, L. M., Flaherty, L., Kefford, R., et al. (2013). Phase III trial of carboplatin and paclitaxel with or without sorafenib in metastatic melanoma. J Clin Oncol, 31(3), 373-379.
106. Chapman, P. B., Einhorn, L. H., Meyers, M. L., Saxman, S., Destro, A. N., Panageas, K. S., et al. (1999). Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. Journal of Clinical Oncology, 17(9), 2745-2751.
107. Middleton, M. R., Grob, J. J., Aaronson, N., Fierlbeck, G., Tilgen, W., Seiter, S., et al. (2000). Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. Journal of Clinical Oncology, 18(1), 158-166.
108. Avril, M. F., Aamdal, S., Grob, J. J., Hauschild, A., Mohr, P., Bonerandi, J. J., et al. (2004). Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study. Journal of Clinical Oncology, 22(6), 1118-1125.
109. McDermott, D. F., Sosman, J. A., Gonzalez, R., Hodi, F. S., Linette, G. P., Richards, J., et al. (2008). Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group. Journal of Clinical Oncology, 26(13), 2178-2185.
110. Wilhelm, S., Carter, C., Lynch, M., Lowinger, T., Dumas, J., Smith, R. A., et al. (2006). Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nature Reviews Drug Discovery, 5(10), 835-844.
111. Falchook, G. S., Long, G. V., Kurzrock, R., Kim, K. B., Arkenau, T. H., Brown, M. P., et al. (2012). Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. The Lancet, 379(9829), 1893-1901.
112. Hauschild, A., Grob, J. J., Demidov, L. V., Jouary, T., Gutzmer, R., Millward, M., et al. (2012). Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. The Lancet, 380(9839), 358-365.
113. Long, G. V., Trefzer, U., Davies, M. A., Kefford, R. F., Ascierto, P. A., Chapman, P. B., et al. (2012). Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. The Lancet Oncology, 13(11), 1087-1095.
114. Bollag, G., Hirth, P., Tsai, J., Zhang, J., Ibrahim, P. N., Cho, H., et al. (2010). Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature, 467(7315), 596-599.
115. Bollag, G., Tsai, J., Zhang, J., Zhang, C., Ibrahim, P., Nolop, K., et al. (2012). Vemurafenib: the first drug approved for BRAF-mutant cancer. Nature Reviews. Drug Discovery, 11(11), 873-886.
116. Yang, H., Higgins, B., Kolinsky, K., Packman, K., Go, Z., Iyer, R., et al. (2010). RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models. Cancer Research, 70(13), 5518-5527.
117. Tsai, J., Lee, J. T., Wang, W., Zhang, J., Cho, H., Mamo, S., et al. (2008). Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proceedings of the National Academy of Sciences of the United States of America, 105(8), 3041-3046.
118. Flaherty, K. T., Puzanov, I., Kim, K. B., Ribas, A., McArthur, G. A., Sosman, J. A., et al. (2010). Inhibition of mutated, activated BRAF in metastatic melanoma. The New England Journal of Medicine, 363(9), 809-819.
119. Ribas, A., & Flaherty, K. T. (2011). BRAF targeted therapy changes the treatment paradigm in melanoma. Nature Reviews Clinical Oncology, 8(7), 426-433.
120. Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., et al. (2011). Improved survival with vemurafenib in melanoma with BRAF V600E mutation. The New England Journal of Medicine, 364(26), 2507-2516.
121. Halaban, R., Zhang, W., Bacchiocchi, A., Cheng, E., Parisi, F., Ariyan, S., et al. (2010). PLX4032, a selective BRAF(V600E) kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF melanoma cells. Pigment Cell & Melanoma Research, 23(2), 190-200.
122. Das Thakur, M., Salangsang, F., Landman, A. S., Sellers, W. R., Pryer, N. K., Levesque, M. P., et al. (2013). Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance. Nature, 494(7436), 251-255.
123. Tseng, J. R., Stuart, D., Aardalen, K., Kaplan, A., Aziz, N., Hughes, N. P., et al. (2011). Use of DNA microarray and small animal positron emission tomography in preclinical drug evaluation of RAF265, a novel B-Raf/VEGFR-2 inhibitor. Neoplasia, 13(3), 266-275.
124. Su, Y., Vilgelm, A. E., Kelley, M. C., Hawkins, O. E., Liu, Y., Boyd, K. L., et al. (2012). RAF265 inhibits the growth of advanced human melanoma tumors. Clinical Cancer Research, 18(8), 2184-2198.
125. Montagut, C., & Settleman, J. (2009). Targeting the RAF-MEK-ERK pathway in cancer therapy. Cancer Letters, 283(2), 125-134.
126. Brower, V. (2010). BRAF inhibitors: research accelerates in wake of positive findings. Journal of the National Cancer Institute, 102(4), 214-215.
127. Hoeflich, K. P., Herter, S., Tien, J., Wong, L., Berry, L., Chan, J., et al. (2009). Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression. Cancer Research, 69(7), 3042-3051.
128. King, A. J., Patrick, D. R., Batorsky, R. S., Ho, M. L., Do, H. T., Zhang, S. Y., et al. (2006). Demonstration of a genetic therapeutic index for tumors expressing oncogenic BRAF by the kinase inhibitor SB-590885. Cancer Research, 66(23), 11100-11105.
129. Menzies, A. M., Long, G. V., & Murali, R. (2012). Dabrafenib and its potential for the treatment of metastatic melanoma. Drug Design, Development and Therapy, 6, 391-405.
130. Eum, K. H., Ahn, S. K., Kang, H., & Lee, M. (2013). Differential inhibitory effects of two Raf-targeting drugs, sorafenib and PLX4720, on the growth of multidrug-resistant cells. Molecular and Cellular Biochemistry, 372(1-2), 65-74.
131. James, J., Ruggeri, B., Armstrong, R. C., Rowbottom, M. W., Jones-Bolin, S., Gunawardane, R. N., et al. (2012). CEP-32496: a novel orally active BRAF(V600E) inhibitor with selective cellular and in vivo antitumor activity. Molecular Cancer Therapeutics, 11(4), 930-941.
132. Seger, R., Ahn, N. G., Posada, J., Munar, E. S., Jensen, A. M., Cooper, J. A., et al. (1992). Purification and characterization of mitogen-activated protein kinase activator(s) from epidermal growth factor-stimulated A431 cells. The Journal of Biological Chemistry, 267(20), 14373-14381.
133. Nikolaev, S. I., Rimoldi, D., Iseli, C., Valsesia, A., Robyr, D., Gehrig, C., et al. (2012). Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma. Nature Genetics, 44(2), 133-139.
134. Wagle, N., Emery, C., Berger, M. F., Davis, M. J., Sawyer, A., Pochanard, P., et al. (2011). Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. Journal of Clinical Oncology, 29(22), 3085-3096.
135. Solit, D. B., Garraway, L. A., Pratilas, C. A., Sawai, A., Getz, G., Basso, A., et al. (2006). BRAF mutation predicts sensitivity to MEK inhibition. Nature, 439(7074), 358-362.
136. Sebolt-Leopold, J. S., Dudley, D. T., Herrera, R., Van Becelaere, K., Wiland, A., Gowan, R. C., et al. (1999). Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo. Nature Medicine, 5(7), 810-816.
137. Alessi, D. R., Cuenda, A., Cohen, P., Dudley, D. T., & Saltiel, A. R. (1995). PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo. The Journal of Biological Chemistry, 270(46), 27489-27494.
138. Cross, D. A. E., & Smythe, C. (1998). PD98059 prevents establishment of the spindle assembly checkpoint and inhibits the G(2)-M transition in meiotic but not mitotic cell cycles in Xenopus. Experimental Cell Research, 241(1), 12-22.
139. Ge, X., Fu, Y. M., & Meadows, G. G. (2002). U0126, a mitogen-activated protein kinase kinase inhibitor, inhibits the invasion of human A375 melanoma cells. Cancer Letters, 179(2), 133-140.
140. Lorusso, P. M., Adjei, A. A., Varterasian, M., Gadgeel, S., Reid, J., Mitchell, D. Y., et al. (2005). Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies. Journal of Clinical Oncology, 23(23), 5281-5293.
141. Rinehart, J., Adjei, A. A., Lorusso, P. M., Waterhouse, D., Hecht, J. R., Natale, R. B., et al. (2004). Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer. Journal of Clinical Oncology, 22(22), 4456-4462.
142. Boasberg, P. D., Redfern, C. H., Daniels, G. A., Bodkin, D., Garrett, C. R., & Ricart, A. D. (2011). Pilot study of PD-0325901 in previously treated patients with advanced melanoma, breast cancer, and colon cancer. Cancer Chemotherapy and Pharmacology, 68(2), 547-552.
143. Yeh, T. C., Marsh, V., Bernat, B. A., Ballard, J., Colwell, H., Evans, R. J., et al. (2007). Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor. Clinical Cancer Research, 13(5), 1576-1583.
144. Haass, N. K., Sproesser, K., Nguyen, T. K., Contractor, R., Medina, C. A., Nathanson, K. L., et al. (2008). The mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor AZD6244 (ARRY-142886) induces growth arrest in melanoma cells and tumor regression when combined with docetaxel. Clinical Cancer Research, 14(1), 230-239.
145. Gopal, Y. N., Deng, W., Woodman, S. E., Komurov, K., Ram, P., Smith, P. D., et al. (2010). Basal and treatment-induced activation of AKT mediates resistance to cell death by AZD6244 (ARRY-142886) in Braf-mutant human cutaneous melanoma cells. Cancer Research, 70(21), 8736-8747.
146. Adjei, A. A., Cohen, R. B., Franklin, W., Morris, C., Wilson, D., Molina, J. R., et al. (2008). Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. Journal of Clinical Oncology, 26(13), 2139-2146.
147. Banerji, U., Camidge, D. R., Verheul, H. M., Agarwal, R., Sarker, D., Kaye, S. B., et al. (2010). The first-in-human study of the hydrogen sulfate (Hyd-sulfate) capsule of the MEK1/2 inhibitor AZD6244 (ARRY-142886): a phase I open-label multicenter trial in patients with advanced cancer. Clinical Cancer Research, 16(5), 1613-1623.
148. Patel, S. P., & Kim, K. B. (2012). Selumetinib (AZD6244; ARRY-142886) in the treatment of metastatic melanoma. Expert Opinion on Investigational Drugs, 21(4), 531-539.
149. Bodoky, G., Timcheva, C., Spigel, D. R., La Stella, P. J., Ciuleanu, T. E., Pover, G., et al. (2012). A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy. Investigational New Drugs, 30(3), 1216-1223.
150. Gilmartin, A. G., Bleam, M. R., Groy, A., Moss, K. G., Minthorn, E. A., Kulkarni, S. G., et al. (2011). GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition. Clinical Cancer Research, 17(5), 989-1000.
151. Infante, J. R., Fecher, L. A., Falchook, G. S., Nallapareddy, S., Gordon, M. S., Becerra, C., et al. (2012). Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial. The Lancet Oncology, 13(8), 773-781.
152. Falchook, G. S., Lewis, K. D., Infante, J. R., Gordon, M. S., Vogelzang, N. J., DeMarini, D. J., et al. (2012). Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial. The Lancet Oncology, 13(8), 782-789.
153. Kim, K. B., Kefford, R., Pavlick, A. C., Infante, J. R., Ribas, A., Sosman, J. A., et al. (2013). Phase II study of the MEK1/MEK2 inhibitor trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor. J Clin Oncol, 31(4), 482-489.
154. Flaherty, K. T., Robert, C., Hersey, P., Nathan, P., Garbe, C., Milhem, M., et al. (2012). Improved survival with MEK inhibition in BRAF-mutated melanoma. The New England Journal of Medicine, 367(2), 107-114.
155. Finn, R. S., Javle, M. M., Tan Jr, B. R., Weekes, C. C., Bendell, J. C., Patnaik, A., et al. (2012). A phase 1 study of MEK inhibitor MEK162 (ARRY-438162) in patients with biliary tract cancer. ASCO Gastrointestinal Cancers Symtosium; Sanfrancisco, CA, USA, Nov 12-16, 2011, abstr 220.
156. Ascierto, P., Berking, C., Agarwala, S., et al. (2012). Efficacy and safety of oral MEK162 in patients with locally advanced and unresectable or metastatic cutaneous melanoma harboring BRAFV600 or NRAS mutations. J Clin Oncol, 30, suppl; abstr 8511.
157. Ascierto, P. A., Schadendorf, D., Berking, C., Agarwala, S. S., van Herpen, C. M., Queirolo, P., et al. (2013). MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. The Lancet Oncology, 14(3), 249-256.
158. Sosman, J. A., Kim, K. B., Schuchter, L., Gonzalez, R., Pavlick, A. C., Weber, J. S., et al. (2012). Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. The New England Journal of Medicine, 366(8), 707-714.
159. Montagut, C., Sharma, S. V., Shioda, T., McDermott, U., Ulman, M., Ulkus, L. E., et al. (2008). Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma. Cancer Research, 68(12), 4853-4861.
160. Johannessen, C. M., Boehm, J. S., Kim, S. Y., Thomas, S. R., Wardwell, L., Johnson, L. A., et al. (2010). COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature, 468(7326), 968-972.
161. Nazarian, R., Shi, H., Wang, Q., Kong, X., Koya, R. C., Lee, H., et al. (2010). Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature, 468(7326), 973-977.
162. Poulikakos, P. I., Persaud, Y., Janakiraman, M., Kong, X., Ng, C., Moriceau, G., et al. (2011). RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature, 480(7377), 387-390.
163. Clement, B. (2012). Control of hepatocellular carcinoma progression by the tumor micro-environment. Bulletin de l'Académie Nationale de Médecine, 196(1), 75-84.
164. Villanueva, J., Vultur, A., Lee, J. T., Somasundaram, R., Fukunaga-Kalabis, M., Cipolla, A. K., et al. (2010). Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell, 18(6), 683-695.
165. Paraiso, K. H., Xiang, Y., Rebecca, V. W., Abel, E. V., Chen, Y. A., Munko, A. C., et al. (2011). PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression. Cancer Research, 71(7), 2750-2760.
166. Flaherty, K. T., Infante, J. R., Daud, A., Gonzalez, R., Kefford, R. F., Sosman, J., et al. (2012). Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. The New England Journal of Medicine, 367(18), 1694-1703.
167. Granville, C. A., Memmott, R. M., Gills, J. J., & Dennis, P. A. (2006). Handicapping the race to develop inhibitors of the phosphoinositide 3-kinase/Akt/mammalian target of rapamycin pathway. Clinical Cancer Research, 12(3 Pt 1), 679-689.
168. Deng, W., Gopal, Y. N., Scott, A., Chen, G., Woodman, S. E., & Davies, M. A. (2012). Role and therapeutic potential of PI3K-mTOR signaling in de novo resistance to BRAF inhibition. Pigment Cell & Melanoma Research, 25(2), 248-258.
169. Davar, D., Tarhini, A. A., & Kirkwood, J. M. (2012). Adjuvant therapy for melanoma. Cancer Journal, 18(2), 192-202.
170. Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., et al. (2010). Improved survival with ipilimumab in patients with metastatic melanoma. The New England Journal of Medicine, 363(8), 711-723.
171. Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., et al. (2011). Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. The New England Journal of Medicine, 364(26), 2517-2526.